Global Continuous Glucose Monitoring Market Size, Share and Trends Analysis
Global CGM market valued at US$9.8 Bn (2023), projected to reach US$36.7 Bn by 2032 at 15.8% CAGR.
$9.8B
$36.7B
15.8%
North America
Executive Summary
The global continuous glucose monitoring market was valued at US$9.8 Bn in 2023 and is projected to reach US$36.7 Bn by 2032, growing at a 15.8% CAGR. North America dominates with 42% share. Dexcom and Abbott lead the competitive landscape. Real-time CGM holds 62% product share while flash monitoring is the fastest-growing segment. Expansion into consumer wellness and APAC markets presents significant growth opportunities.
Key Highlights
North America leads with 42% share driven by high diabetes prevalence and favorable reimbursement policies.
Real-time CGM dominates with 62% product share; flash monitoring is the fastest-growing segment.
Dexcom and Abbott together command over 60% of the global CGM market revenue.
Market Overview
Market Context
The global CGM market is driven by rising diabetes prevalence, technological advancements in sensor accuracy, and expanding insurance coverage. Real-time CGM leads adoption, while flash monitoring gains traction in cost-sensitive markets. Integration with insulin pumps and digital health platforms accelerates growth.
The global CGM market is experiencing high growth driven by rising diabetes prevalence, sensor technology advancements, and expanding reimbursement coverage. Real-time CGM leads adoption while flash monitoring gains share in cost-sensitive regions. Integration with closed-loop insulin delivery and digital health platforms further accelerates market expansion.
Market Stage
High growth
Adoption Level
Growing
Key Trends
Market Forecast & Data
Base Year (2023)
$9.8B
Forecast (2032)
$36.7B
CAGR (2024-2032)
15.8%
| Year | Market size ($ Billion) |
|---|---|
| 2023Base year | $9.80B |
| 2024 | $11.35B |
| 2025 | $13.14B |
| 2026 | $15.22B |
| 2027 | $17.62B |
| 2028 | $20.41B |
| 2029 | $23.63B |
| 2030 | $27.36B |
| 2031 | $31.69B |
| 2032 | $36.69B |
The CGM market will grow from US$9.8 Bn in 2023 to US$36.7 Bn by 2032 at a 15.8% CAGR. Growth is fueled by expanding diabetic populations, AI-driven analytics, and consumer wellness adoption. Asia Pacific will outpace other regions, while real-time CGM maintains dominance.
| Region | Market share | Growth rate | Largest market |
|---|---|---|---|
| North America | 42.0% | 14.2% | United States |
| Europe | 29.0% | 16.5% | Germany |
| Asia Pacific | 29.0% | 18.8% | China |
North America
#1Largest market: United States
Europe
#2Largest market: Germany
Market Dynamics
- Rising global diabetes prevalence and incidence rates
- Technological advances improving sensor accuracy and wearability
- Expanding insurance and reimbursement coverage globally
Market Segmentation
| Segment | Share |
|---|---|
| HospitalsLargest end-user segment driven by inpatient monitoring and critical care applications. | 40.0% |
| Home Care SettingsFast-growing segment as patients increasingly prefer remote self-monitoring solutions. | 35.0% |
| Clinics & Diagnostic CentersAdopts CGM for outpatient diabetes management and diagnostic screening programs. | 25.0% |
| Total | 100.0% |
| Segment | Share |
|---|---|
| Real-Time CGM (RT-CGM)Provides continuous real-time glucose readings transmitted to a receiver or smartphone; leads the market with broad clinical adoption. | 62.0% |
| Flash Glucose Monitoring (FGM)Requires user-initiated scanning for glucose data; growing in cost-sensitive markets due to lower price points. | 38.0% |
| Total | 100.0% |
By End User List
- Hospitals
- Home Care Settings
- Clinics & Diagnostic Centers
Regional Analysis
North America
Lead: United StatesLargest market driven by high diabetes prevalence, favorable reimbursement, and presence of Dexcom and Abbott headquarters.
Europe
Lead: GermanyGrowing rapidly due to EU MDR compliance improvements, rising type 2 diabetes cases, and expanding NHS coverage in the UK.
Asia Pacific
Lead: ChinaFastest-growing region fueled by massive diabetic population, increasing healthcare spending, and growing awareness of CGM technology.
Country-Level Analysis
| Country | Share | Growth |
|---|---|---|
| United States | 38.0% | +13.5% |
| Germany | 8.0% | +15.2% |
| China | 12.0% | +22.4% |
Competitive Landscape
Dexcom, Inc.
United States
Dominates standalone CGM revenue with the G7 system, covered by all major U.S. PBMs and reaching over 6 million eligible patients globally.
U.S.-based market leader in standalone CGM systems known for the G7 real-time platform with 15-day sensor wear and broad PBM coverage.
Abbott Laboratories
United States
Second-largest globally with the FreeStyle Libre franchise targeting US$10 Bn in franchise sales by 2028; launched consumer Lingo CGM in 2024.
Global healthcare giant and #2 CGM provider with the FreeStyle Libre franchise targeting US$10 Bn in franchise sales by 2028.
Medtronic plc
Ireland
Offers Guardian Sensor 4 integrated with its MiniMed insulin pump systems, focusing on closed-loop automated insulin delivery solutions.
Ireland-headquartered medtech leader integrating CGM with its MiniMed insulin pump portfolio for automated closed-loop insulin delivery.
Recent Developments
Dexcom G7 receives expanded pediatric indication globally and secures coverage with all three major U.S. PBMs.
Abbott launches Lingo consumer CGM system targeting non-diabetic users for general health and wellness optimization.
Regulatory Landscape
Research Methodology
Primary research
- Expert interviews
- Surveys
Secondary research
- Industry reports
- Company financials
Validation: Triangulation method
Strategic Takeaways
The CGM market offers high-growth potential, particularly in APAC and real-time CGM segments, with strong double-digit CAGR expected through 2032.
Focus on emerging market expansion, software integration, and next-gen sensor accuracy to capture growing demand for continuous glucose monitoring.
Frequently Asked Questions
Related research
Reports in the same field, each with its base-year figure and the growth rate it is published at.
- Medical DevicesGlobal Asia Pacific Continuous Glucose Monitoring Market$10.0B · 20.9% CAGR
- Medical DevicesGlobal Europe Continuous Glucose Monitoring Market$10.0B · 19.6% CAGR
- Medical DevicesGlobal North America Continuous Glucose Monitoring Market$9.5B · 16% CAGR
- Medical DevicesGlobal United States Continuous Glucose Monitoring Market$3.8B · 16.5% CAGR
- Healthcare ITGlobal Remote Patient Monitoring Market$26.0B · 19.9% CAGR
- Healthcare ITNorth America Remote Patient Monitoring Market$24.0B · 13.5% CAGR